[go: up one dir, main page]

WO2012018538A3 - Bioassays for determining pd-1 modulation - Google Patents

Bioassays for determining pd-1 modulation Download PDF

Info

Publication number
WO2012018538A3
WO2012018538A3 PCT/US2011/044798 US2011044798W WO2012018538A3 WO 2012018538 A3 WO2012018538 A3 WO 2012018538A3 US 2011044798 W US2011044798 W US 2011044798W WO 2012018538 A3 WO2012018538 A3 WO 2012018538A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioassays
monitoring
treatment regimens
modulation
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/044798
Other languages
French (fr)
Other versions
WO2012018538A2 (en
Inventor
Gregory John Carven
Gradus Johannes Dulos
Jeroen Elassaiss-Schaap
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Merck Sharp and Dohme LLC
Original Assignee
MSD Oss BV
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD Oss BV, Schering Corp filed Critical MSD Oss BV
Publication of WO2012018538A2 publication Critical patent/WO2012018538A2/en
Publication of WO2012018538A3 publication Critical patent/WO2012018538A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the identification and use of cytokine markers in bioassays for use in monitoring, diagnostic, patient selection, and treatment regimens involving blockade of the PD-1 pathway. In certain aspects, the invention provides methods and kits relating to these bioassays for selection and/or monitoring of treatment regimens involving PD-1 blockade. Biomarkers, kits, treatment regimens, therapeutic monitoring, and diagnostic methods related to anti-PD-1 therapies are provided.
PCT/US2011/044798 2010-07-26 2011-07-21 Bioassays for determining pd-1 modulation Ceased WO2012018538A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36765710P 2010-07-26 2010-07-26
US61/367,657 2010-07-26

Publications (2)

Publication Number Publication Date
WO2012018538A2 WO2012018538A2 (en) 2012-02-09
WO2012018538A3 true WO2012018538A3 (en) 2012-05-03

Family

ID=45559972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/044798 Ceased WO2012018538A2 (en) 2010-07-26 2011-07-21 Bioassays for determining pd-1 modulation

Country Status (1)

Country Link
WO (1) WO2012018538A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX341076B (en) 2011-03-31 2016-08-04 Merck Sharp & Dohme Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
US9863935B2 (en) 2012-05-08 2018-01-09 H. Lee Moffitt Cancer And Research Institute, Inc. Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3084003A4 (en) * 2013-12-17 2017-07-19 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp TIM-3 Antibody Molecules and Their Uses
LT3116909T (en) 2014-03-14 2020-02-10 Novartis Ag ANTI-BODY MOLECULES AGAINST LAG-3 AND THEIR USE
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
MA42447A (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3707272A4 (en) * 2017-11-09 2021-11-24 The Trustees of The University of Pennsylvania EXTRACELLULAR VESICULAR PROTEINS AND THEIR USE FOR CANCER DIAGNOSIS, PREDICTION OF RESPONSE TO THERAPY AND TREATMENT
WO2019126736A1 (en) * 2017-12-21 2019-06-27 New York University Pd-1 related cancer therapy
BR112021008873A8 (en) 2018-11-07 2023-04-11 Merck Sharp & Dohme FORMULATION
RU2731896C1 (en) * 2019-07-04 2020-09-09 Закрытое Акционерное Общество "Биокад" Test system for analysing functional activity of antibodies against pd-1 and antibodies against pd-l1
AU2021347967A1 (en) 2020-09-24 2023-06-01 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
JP2024505524A (en) 2021-01-29 2024-02-06 メルク・シャープ・アンド・ドーム・エルエルシー Compositions of programmed death receptor 1 (PD-1) antibodies and methods for obtaining the compositions
WO2025006973A2 (en) * 2023-06-29 2025-01-02 Board Of Regents, The University Of Texas System Methods for treating immune related adverse events

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
US20100055102A1 (en) * 2008-08-25 2010-03-04 Solomon Langermann Compositions of pd-1 antagonists and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
US20100055102A1 (en) * 2008-08-25 2010-03-04 Solomon Langermann Compositions of pd-1 antagonists and methods of use

Also Published As

Publication number Publication date
WO2012018538A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
WO2012018538A3 (en) Bioassays for determining pd-1 modulation
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
WO2011151252A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
HK1204995A1 (en) Compounds and methods for kinase modulation, and indications therefor
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
WO2009054996A8 (en) Systems and methods for viral therapy
UA107827C2 (en) ANTIBODY TO CD40
EP2582722A4 (en) ANTI-GD2 ANTIBODIES
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EP4356960A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
EA201590247A1 (en) ANTIBODIES TO SIGLEC-15
WO2012170704A3 (en) Methods and compositions of predicting activity of retinoid x receptor modulator
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
IN2012DN06309A (en)
HK1214632A1 (en) Methods of using biomarkers for the treatment of cancer by modulation of bcl2!expression
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
HK1214752A1 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
WO2014043633A8 (en) Use of e-cadherin and vimentin for selection of treatment responsive patients
EP2666019A1 (en) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815010

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815010

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14234063

Country of ref document: US